|
DSpace at RU >
University Library >
Academic bibliography >
|
| Title: | Efficacy of the pulsed dye laser in the treatment of localized recalcitrant plaque psoriasis: a comparative study. |
| Author(s): | Erceg, A. (298209594) Bovenschen, H.J. (298209055) Kerkhof, P.C.M. van de (069296987) Seyger, M.M.B. (29897522X) |
| Publication year: | 2006 |
| Document type: | Article / Letter to editor |
| Journal: | British journal of dermatology |
| ISSN: | 0007-0963 |
| Volume: | vol. 155 |
| Issue: | iss. 1 |
| Start page: | p. 110 |
| End page: | p. 114 |
| Abstract: | BACKGROUND: Localized chronic plaque psoriasis, resistant to local therapy, may be very hard to treat. The treatment of these lesions with a pulsed dye laser (PDL) has been described before, but a comparative study between the PDL and a potent topical treatment has never been performed. OBJECTIVES: To compare the efficacy of the PDL in the treatment of localized, recalcitrant plaque psoriasis with a potent topical therapy, using calcipotriol/betamethasone dipropionate (Dovobet) as an active comparator. METHODS: Eight patients with psoriasis were treated with both PDL (585 nm) and calcipotriol/betamethasone dipropionate in an open, intrapatient, left-right comparison. A plaque severity score (sum score) and photographs were used to document the course of therapy. Patients reported pain on a visual analogue scale. RESULTS: Both treatments were well tolerated, although one patient left the study due to post-PDL treatment pain. A significant difference in the sum score 12 weeks after treatment was seen in favour of the PDL (62% vs. 19% reduction; P<0.05). Scores for erythema declined significantly at week 12 in both the PDL and the calcipotriol/betamethasone dipropionate group (P<0.001). Induration and desquamation scores were significantly reduced at week 12 in the PDL group, without a statistically significant reduction in calcipotriol/betamethasone-treated lesions. The pain scores declined with progressive PDL treatments, although not statistically significantly. CONCLUSIONS: PDL treatment might be considered for the treatment of localized, recalcitrant plaque psoriasis, when other topical therapies have failed. |
| Subject: | CTR 2: Clinical Pharmacology and physiology UMCN 4.2: Chronic inflammation and autoimmunity |
| Organization: | Dermatology |
| Appears in Collections: | Academic bibliography
|
|
Please use this identifier to cite or link to this item:
http://hdl.handle.net/2066/49399
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|
|